{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:59:23Z","timestamp":1772251163130,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["GPP3"],"award-info":[{"award-number":["GPP3"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>Umibecestat, an orally active \u03b2\u2010secretase inhibitor, reduces the production of amyloid beta\u2010peptide that accumulates in the brain of patients with Alzheimer\u2019s disease. The echocardiogram effects of umibecestat, on QTcF (Fridericia\u2010corrected QT), on PR and QRS and heart rate (HR), were estimated by concentration\u2010effect modeling. Three phase I\/II studies with durations up to 3\u00a0months, with 372 healthy subjects over a wide age range, including both sexes and 2 ethnicities, were pooled, providing a large data set with good statistical power. No clinically relevant effect on QTcF, PR interval, QRS duration, or HR were observed up to supratherapeutic doses. The upper bound of 90% confidence intervals of the \u2206QTcF was below the 10\u00a0ms threshold of regulatory concern for all concentrations measured. Prespecified sensitivity analysis confirmed the results in both sexes, in those over and below 60\u00a0years, and in Japanese subjects. All conclusions were endorsed by the US Food and Drug Administration (FDA).<\/jats:p>","DOI":"10.1111\/cts.12832","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T10:25:37Z","timestamp":1593080737000},"page":"1316-1326","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Pooled Analysis of Three Randomized Phase I\/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat"],"prefix":"10.1111","volume":"13","author":[{"given":"Stefan Viktor","family":"Vormfelde","sequence":"first","affiliation":[{"name":"Department of Translational Medicine Novartis Institutes for BioMedical Research Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Pezous","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Novartis Institutes for BioMedical Research Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Lef\u00e8vre","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Novartis Institutes for BioMedical Research Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carine","family":"Kolly","sequence":"additional","affiliation":[{"name":"Department of Preclinical Safety Novartis Institutes for BioMedical Research Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Neumann","sequence":"additional","affiliation":[{"name":"Department of Neuroscience Novartis Institutes for BioMedical Research Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Jordaan","sequence":"additional","affiliation":[{"name":"Cardiovascular Safety Expert \u2013 CMO and Patient Safety \u2013 Oncology Novartis Pharma Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Ufer","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Novartis Institutes for BioMedical Research Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Legangneux","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Novartis Institutes for BioMedical Research Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30403-4"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.05.008"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606210"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.08.005"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2006-9S318"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11283"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005615"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4018"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01124-1"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3647-11.2011"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"e9316","DOI":"10.15252\/emmm.201809316","article-title":"The BACE\u20101 inhibitor CNP520 for prevention trials in Alzheimer\u2019s disease","author":"Neumann U.","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"e_1_2_11_12_1","first-page":"242","article-title":"Alzheimer\u2019s prevention initiative generation program: evaluating CNP520 efficacy in the prevention of Alzheimer\u2019s disease","volume":"4","author":"Lopez Lopez C.","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.02.005"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812840"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1813435"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.108.789081"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2018.1418319"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2015.143"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9558-5"},{"key":"e_1_2_11_20_1","unstructured":"International Conference on Harmonization (ICH).ICH harmonised tripartite guideline E14: The clinical evaluation of Qt\/Qtc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs. <https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Guideline.pdf>. Accessed July 4 2019."},{"key":"e_1_2_11_21_1","unstructured":"International Conference on Harmonization (ICH).ICH Clinical Evaluation of QT Final Concept Paper E14 Q&As (R3): Revision of ICH E14 Q&As (R2). <https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Q_A_R3__Final_Concept_Paper_9June_2015.pdf\u2265. Accessed July 4 2019."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.785"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12405"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9704"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1087"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.155"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001615"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00597"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.60"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.12832","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T09:30:59Z","timestamp":1693819859000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/cts.12832"],"URL":"https:\/\/doi.org\/10.1111\/cts.12832","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"2020-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}